55 results about "Ischemic cardiomyopathy" patented technology

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and / or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and / or applying to the patient a therapeutically effective amount of stem cells and / or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.

Disclosed are single nucleotide polymorphisms (SNIps) associated with breast cancer, lung cancer, prostate cancer, non-insulin dependent diabetes, end stage renal disease due to non-insulin dependent diabetes, hypertension, end stage renal disease F due to hypertension, myocardial infarction, colon cancer, hypertension, atherosclerotic peripheral vascular disease due to hypertension, cerebrovascular accident due to hypertension, cataracts due to hypertension, cardiomyopathy with hypertension, myocardial infarction due to hypertension, non-insulin dependent diabetes mellitus, atherosclerotic peripheral vascular disease due to non-insulin dependent diabetes mellitus, cerebrovascular accident due to non-insulin dependent diabetes mellitus, ischemic cardiomyopathy, ischemic cardiomyopathy with non-insulin dependent diabetes mellitus, myocardial infarction due to non-insulin dependent diabetes mellitus, atrial fibrillations without valvular disease, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease. cholecystectomy, degenerative joint disease, end stage renal disease and frequent de-clots, end stage renal disease due to focal segmental glomerular sclerosis, end stage renal disease due to insulin dependent diabetes mellitus, or seizure disorder. Also disclosed are methods for using SNPs to determine susceptibility to these diseases; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs.

The invention relates to a method for preparing a chitosan-silk fibroin composite nano-fiber multifunctional patch for promoting myocardial tissue regeneration and monitoring stem cells. The method comprises the following steps: preparing a cellulose nano-fiber basal plate by an electrostatic spinning technology; alternately assembling positively charged chitosan (CS) and negatively charged silk fibroin (SF) to the surface of nano-fibers layer by layer by adopting a layer-by-layer assembly technique, and assembling 5.5-10.5 layers to form a CS-SF composite nano-fiber membrane; and planting seed cells of adipose tissue-derived stromal cells or cardiac progenitor cells labeled by green fluorescent protein and firefly luciferase on the surface of the CS-SF composite nano-fiber membrane, preparing the patch by three-dimensional co-culture. The patch has excellent biocompatibility, can be used as a cell vector, has an effect of resisting oxidative stress to improve the survival rate and treatment efficiency of stem cells, and is capable of evaluating the number, distribution and function states of transplanted stem cells, effectively preventing occurrence of post-myocardial infarction heart failure and reducing the death rate of ischemic cardiomyopathy.

Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and / or applying to the patient a therapeutically effective amount of stem cells and / or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.

The invention discloses a medicine composition for ischemic diseases, which comprises the following raw materials by weight portion: 5 to 15 portions of radix astragali, 2 to 8 portions of Salvia miltiorrhiza, 1 to 5 portions of ligusticum wallichii, 1 to 5 portions of safflower and 1 to 3 portions of earthworms. The invention simultaneously discloses application of the medicine composition in preparing pharmaceutical preparation for treating ischemic cerebrovascular disorder, application of the medicine composition in pharmaceutical preparation for treating ischemic cardiomyopathy, and application of the medicine composition in pharmaceutical preparation for treating ischemic enteropathy. The medicine composition can be used for preventing and treating ischemic diseases such as ischemic cerebrovascular disorder, ischemic cardiomyopathy and ischemic enteropathy, and can also be used for treating coronary heart disease, arteriosclerosis and mesenteric vein embolism. The medicine composition has strong pertinence and obvious medicine effect, and provides more application selections for clinical medication.

This invention provides a system and a method for monitoring a patient's Formation number (Fn) and comparing the measured Fn to the baseline data of healthy persons population or to the patient's past history data to assess the degree of ventricular and / or valvular dysfunction, wherein the valvular dysfunction may comprise dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, restrictive cardiomyopathy, or the like.

The invention belongs to the Chinese medicine pharmaceutical field and relates to the application of specific monomer leonurine in Chinese medicinal herb motherwort in preparing medicine combination, in particular to the application in preparing the medicine combination which cures ischemic cardiomyopathy. By the experimental research of anoxic myocardium models in vitro, the result shows that the leonurine can increase livability of ischemic myocyte, can decrease the leakage rate of lactate dehydrogenase, can increase the activity of antioxidase catalase, can increase the activity of SOD, can minish the level of lipid peroxidation products, and proves that the leonurine has obvious protective effect on ischemic myocardium and prepares the medicine which cures ischemic cardiomyopathy.

The invention discloses a stem cell preparation for treating ischemic cardiomyopathy and a preparation method of the stem cell preparation. The preparation consists of mesenchymal stem cells, cardiac stem cells and vascular endothelial stem cells, and a solvent is platelet-rich plasma lysate of a patient. The stem cells express a corresponding specific identifier and do not express a corresponding non-specific identifier at the same time. The preparation method comprises the following steps: (1), preparing mesenchymal stem cells between a placenta and an umbilical cord; (2), applying different induction culture systems to induce the mesenchymal stem cells in the step (1) to be cardiac stem cells and vascular endothelial stem cells; (3), preparing the solvent which is the platelet-rich plasma lysate; and (4), uniformly mixing and preparing the stem cell preparation. The stem cell preparation disclosed by the invention is rich in resource, easy to prepare, convenient to collect, and free of pain while being applied; moreover, the stem cell preparation is low in immunological rejection after being transplanted. The stem cell preparation comprises a plurality of stem cells, so that advantages of combined effect of a plurality of cells can be brought into play; the solvent is easily available, and can directly act on a patient; besides, transplantation effect is enhanced.

The invention relates to the traditional Chinese medicine field, and discloses an application of a traditional Chinese medicine in preparation of medicines for preventing and treating ischemic cardiomyopathy. According to the invention, a DPPH method is used for determining the Antlerpilose grass extract which possesses removal capability for oxygen free radical, the result shows that the Antlerpilose grass extract is capable of removing the oxygen free radical by a dosage dependence mode. A H2O2 induced myocardial cell damage model is used for detecting the influence of the oxidative damage survival rate and myocardial cell forms of the H2O2 induced mice myocardial cells by the Antlerpilose grass extract. The result shows that the Antlerpilose grass extract is capable of raising the survival rate of the myocardial cells in the dosage dependent mode, obviously improving the form of the myocardial cells and inhibiting the peroxidative damage. In addition, the Antlerpilose grass extract is capable of obviously reducing the content of LDH and MDA in mice myocardial cells. The experiment in vivo shows that the Antlerpilose grass extract can reduce the myocardial infarction of mice caused by coronary artery occlusion. The invention provides the application of the traditional Chinese medicine in preparation of medicines for preventing or treating ischemic cardiomyopathy.

The invention belongs to the technical field of biological medicine, and particularly relates to a triazolone-thiadiazole compound capable of promoting regeneration of myocardial cells and a drug use of the triazolone-thiadiazole compound. The compound comprises two 3,6-bis-substituted triazolone-thiadiazole derivatives or salts thereof: a chemical structural formula is C14H15N5S, an average molecular weight is 285.37 g / Mol, and the name is 6-cyclohexyl-3-(pyridine-4-yl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole; a chemical structural formula is C13H13N5S, an average molecular weight is 271.37g / mol, and the name is 6-cyclopentyl-3-(pyridine-4-yl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole. An experiment result shows that the small molecular compound is a Wnt / beta-catenin signal channel inhibitor and can effectively promote the proliferation of the myocardial cells and / or restoring the damaged myocardial cells; and an integral-mode animal model experiment shows that the triazolone-thiadiazole compound is hardly toxic, has a further research and application prospect, and can be used for preparing drugs for treating and preventing the diseases such as myocardial infarction, arrhythmia, ischemic cardiomyopathy, cardiac failure and the like.

The invention provides a method for improving the survivability of old people mesenchymal stem cells after transplanting. According to the method, mesenchymal stem cells with passage stability obtained from the bone marrow of old people are put into a conventional culture medium in which 0.5mumol / L SRT1720, 5mM NAD+ and 20mM glutamine are added; pretreatment is performed for 24 hours; the obtained and processed mesenchymal stem cells are used for cell transplanting treatment. The method has the beneficial effects that for the SRT1720 pretreatment, the apoptosis of the old people mesenchymal stem cells under the stress condition can be inhibited through inhibiting an exogenous apoptosis path of the old people mesenchymal stem cells; after the transplanting of the mesenchymal stem cells subjected to the SRT1720 pretreatment, the survival rate in the ischemic myocardium is improved; the effect for treating ischemic cardiomyopathy is obviously improved.

The invention discloses a capsule type coronary oppressing device and a method for manufacturing a chronic myocardial ischemia animal model. The capsule type coronary oppressing device at least comprises a capsule body and an injection pipe communicated with the capsule body. The method for manufacturing a chronic myocardial ischemia animal model includes the steps that firstly, an animal sample is fixed on an experiment table; secondly, a skin is shaved; thirdly, the thoracic cavity is cut open and the heart is exposed; fourthly, the coronary artery is extracted, the capsule body of the capsule type coronary oppressing device is fixed on the myocardium and bundled with the coronary artery, and at least a rubber tube section of the injection pipe of the capsule type coronary oppressing device is fixed below the skin of the animal sample; fifthly, the thorax is closed for feeding. According to the capsule type coronary oppressing device and the method for manufacturing the chronic myocardial ischemia animal model, the chronic myocardial ischemia animal model which can perform multiple times of intermittent ischemia reperfusion on the cardiac muscle and can be continuously studied can be constructed. New ideas and a basis can be provided for treating the ischemic cardiomyopathy in clinic work, and new progresses can be provided for treatment theories of the ischemic cardiomyopathy.

The invention discloses medical application of berberine. The berberine has prominent functions of resisting noradrenaline and stimulating pulmonary arterial smooth muscle cells and is capable of effectively improving the function of a right ventricular, and meanwhile, the berberine is capable of remarkably reducing mean pulmonary arterial pressure; the functions of preventing in-stent restenosis and stent thrombosis are obtained; the berberine has a unique function of preventing and treating myocardial infarction; the berberine is capable of effectively preventing and treating ischemic cardiomyopathy and cardiac failure caused thereby.

The invention relates to a biological power duplex valve device and a charging and discharging method. Dilated cardiomyopathy and ischemic cardiomyopathy are the principal diseases causing congestive heart failure, and have the common pathophysiologic characteristics of atrioventricular valve ring, left ventricular enlargement, atrioventricular valve regurgitation and reduction of ventricular ejection fraction. The biological power duplex valve device comprises a power fluid balloon (1), an in-vitro pump controller (2) and a catheter (3), wherein the power fluid balloon is connected with the catheter, the catheter is connected with a valve ring (4) and a group of holder legs (8), the valve ring is connected with a valve leaflet (5), the valve leaflet is connected with a valve fluid balloon (6), the valve ring is connected with the power fluid balloon, and signals sent by the in-vitro pump controller are received by a magnet of the power fluid balloon. The biological power duplex valve device is applied as a medical appliance.

The invention belongs to the field of traditional Chinese medicines and particularly relates to a preparation method of total flavonoids of clematis filamentosa Dunn and application of the total flavonoids of clematis filamentosa Dunn to a drug for treating myocardial ischemia. The main technical scheme is as follows: whole dried herbs on the overground part of clematis filamentosa Dunn serving as a traditional Chinese medicine are extracted, chromatographically separated and purified to prepare the total flavonoids of clematis filamentosa Dunn, wherein the purity of the total flavonoids of clematis filamentosa Dunn is more than 85%. In-vitro and in-vivo pharmacological experiments prove that the prepared total flavonoids of clematis filamentosa Dunn can be used for treating myocardial ischemia, reducing blood viscosity and reducing platelet aggregation, and have a certain protecting effect for ischemic myocardium cells and a remarkable myocardial ischemia treating effect. The high-purity total flavonoids of clematis filamentosa Dunn are prepared from clematis filamentosa Dunn medicinal materials serving as raw materials through macroporous resin and silica gel chromatographic coupled separation, the total flavonoids of clematis filamentosa Dunn can be prepared into a preparation such as a tablet, a capsule, a dropping pill and a powder injection by adding auxiliary materials, and the preparation can be applied to treatment of myocardial ischemia diseases such as latent coronary heart disease, angina, myocardial infarction and ischemic cardiomyopathy. The preparation method disclosed by the invention is simple and stable in process and is easily produced in batches.

The invention particularly discloses a restricted type cardiomyopathy gene data processing device. The device comprises a basic data acquisition module, an analysis module, an algorithm establishing module, a primary screening module, a re-screening module and an analysis and identification module. Biological function and biological network analysis can be carried out according to screened co-expressed gene pair data to obtain a cardiomyopathy biomarker, and the biomarker is used for recognizing non-cardiomyopathy patients, ischemic cardiomyopathy patients and idiopathic cardiomyopathy patients and researching the pathogenesis of the ischemic cardiomyopathy patients and the idiopathic cardiomyopathy patients. In the co-expressed gene pair data, co-expressed gene pair data including gene data related to the biological metabolism process is obtained, the co-expressed gene pair data is determined as the cardiomyopathy biomarker, and the recognition precision of the cardiomyopathy patients can be improved.

The invention discloses a medicine composition for ischemic diseases, which comprises the following raw materials by weight portion: 5 to 15 portions of radix astragali, 2 to 8 portions of Salvia miltiorrhiza, 1 to 5 portions of ligusticum wallichii, 1 to 5 portions of safflower and 1 to 3 portions of earthworms. The invention simultaneously discloses application of the medicine composition in preparing pharmaceutical preparation for treating ischemic cerebrovascular disorder, application of the medicine composition in pharmaceutical preparation for treating ischemic cardiomyopathy, and application of the medicine composition in pharmaceutical preparation for treating ischemic enteropathy. The medicine composition can be used for preventing and treating ischemic diseases such as ischemic cerebrovascular disorder, ischemic cardiomyopathy and ischemic enteropathy, and can also be used for treating coronary heart disease, arteriosclerosis and mesenteric vein embolism. The medicine composition has strong pertinence and obvious medicine effect, and provides more application selections for clinical medication.

The invention discloses an application of (Z)-2-imino-5-(3,5-dimethoxyphenylmethylene)-1-methylimidazolidinyl-4-one in the preparation of cardiovascular drugs. Specifically, the provided compound has a prominent effect on reducing damage caused by myocardial ischemia / reperfusion; is capable of prominently reducing the infarct volume in left ventricle of myocardial ischemia rats, and is suitable for preparing drugs for preventing and / or treating cardiovascular diseases especially ischemic cardiomyopathy, myocardial ischemia / reperfusion damage, and the like.

The invention relates to a medicine field, in particular relates to application of (Z)-1-methyl-1, 5-dihydro-2-amido-5-(4-(mesyl) benzal)-4H-imidazole-4-ketone and pharmaceutically acceptable salt thereof in the treatment of cardiovascular and cerebrovascular diseases of mammals; the compound and the salt of the compound can effectively prohibit formation of thrombus and are used for preventing or curing diseases such as coronary heart disease, atherosclerosis, artery and vein thrombosis, angina, myocardial infarction, coronary heart disease, myocarditis, ischemic cardiomyopathy, myocardial infarction, cardiovascular complications of diabetes, cerebral haemorrhage, cerebral thrombosis, cerebral embolism, cerebral infarction, brain stroke, lacunar infarction, transient ischemic attack, cerebral arteriosclerosis and peripheral vascular diseases such as obstructive vasculitis, aortoarteritis, hypercholesterolemia, or high blood lipids, etc.

The invention relates to a pharmaceutical composition for preventing and treating myocardial ischemia as well as a preparation and an application thereof. The pharmaceutical composition employs sphingosine-1-phosphate, naproxen and an anticoagulant medicine as medicinal active components, wherein the anticoagulant medicine is selected from heparin, dicoumarol, acetonyl benzyl hydroxycoumarin, aspirin and the like, and preferably dicoumarol. Synergistically interacted multi-path between medicinal active components of the pharmaceutical composition perform effects for prevention and treatment of myocardial ischemia, and improve myocardial ischemic electrocardiogram change and anticoagulation. The pharmaceutical composition can be taken orally or applied parenterally, in order to effectively prevent and treat myocardial ischemia, prevent and alleviate angina pectoris, myocardial infarction or ischemic cardiomyopathy, and the like.

The invention discloses a biomarker related to ischemic cardiomyopathy occurrence and development. A gene is PCYOX1L; high-throughput sequencing finds out that the expression of the PCYOX1L gene in the body of a patient with ischemic cardiomyopathy is up-regulated; further verification proves that the PCYOX1L gene exactly has differential expression in the body of the patient with the ischemic cardiomyopathy and the results shows that the PCYOX1L can be used as the biomarker applied to clinical diagnosis of the ischemic cardiomyopathy.

The present inventors have found that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect to improve the function of the heart, prevent cardiomyocyte hypertrophy, prevent myocardial fibrosis and promote angiogenesis in an animal model with dilated cardiomyopathy, the specific HMGB1 fragment peptide also exhibits an effect to improve the function of the heart, preventauxocardia, prevent cardiomyocyte hypertrophy, prevent myocardial fibrosis and promote angiogenesis in an animal model with ischemic cardiomyopathy associated with old myocardial infarction, and thespecific HMGB1 fragment peptide exhibits an effect to prevent cardiomyocyte hypertrophy and prevent myocardial fibrosis in an animal model with hypertensive cardiomyopathy. On the basis of this finding, a pharmaceutical composition for preventing and / or treating cardiomyopathy, old myocardial infarction, and chronic heart failure associated with these diseases is provided, which contains an HMGB1fragment peptide having a specific amino acid sequence.

The invention discloses a capsule type coronary oppressing device and a method for manufacturing a chronic myocardial ischemia animal model. The capsule type coronary oppressing device at least comprises a capsule body and an injection pipe communicated with the capsule body. The method for manufacturing a chronic myocardial ischemia animal model includes the steps that firstly, an animal sample is fixed on an experiment table; secondly, a skin is shaved; thirdly, the thoracic cavity is cut open and the heart is exposed; fourthly, the coronary artery is extracted, the capsule body of the capsule type coronary oppressing device is fixed on the myocardium and bundled with the coronary artery, and at least a rubber tube section of the injection pipe of the capsule type coronary oppressing device is fixed below the skin of the animal sample; fifthly, the thorax is closed for feeding. According to the capsule type coronary oppressing device and the method for manufacturing the chronic myocardial ischemia animal model, the chronic myocardial ischemia animal model which can perform multiple times of intermittent ischemia reperfusion on the cardiac muscle and can be continuously studied can be constructed. New ideas and a basis can be provided for treating the ischemic cardiomyopathy in clinic work, and new progresses can be provided for treatment theories of the ischemic cardiomyopathy.

The invention belongs to the field of medicines or health products, and particularly relates to the use of catechin and epicatechin compounds in the preparation of drugs for up-regulating the expression level of microRNA-150. As found by researches, catechin, catechin gallate, gallocatechin, (-)-gallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin and epigallocatechin gallatecan up-regulate the expression level of the microRNA-150, and can be used for treating myocardial hypertrophy, hypertension, ischemic cardiomyopathy, myocardial infarction, arrhythmia, cancer or sepsis.

The invention discloses a molecular marker for predicting ischemic cardiomyopathy. The invention discloses the use of the molecular marker EFCC1 or ARHGAP17 in preparation of a product for diagnosingischemic cardiomyopathy, and the invention also discloses a product for diagnosing ischemic cardiomyopathy, the product comprises a reagent for detecting EFCC1 or ARHGAP17. The invention also discloses the use of EFCC1 or ARHGAP17 in constructing a computational model for predicting ischemic cardiomyopathy.

The invention discloses an application of a gene marker in diagnosing ischemic cardiomyopathy. The gene marker is TMEM30B. Expression of the TMEM30B in a patient with cardiomyopathy is up-regulated, and early assisted diagnosis can be provided for the patient with cardiomyopathy by detecting the expression level of a TMEM30B gene, so that early intervention and treatment are achieved, and the survival rate and the life quality of the patient are improved.

The invention discloses use of genes and expression products thereof in ischemic cardiomyopathy. The invention discloses use of COLGALT2 or GTF2E1 in the preparation of a product for diagnosing ischemic cardiomyopathy, and a product for detecting an expression level of COLGALT2 or GTF2E1. The invention also discloses use of COLGALT2 or GTF2E1 in constructing a computational model for predicting ischemic cardiomyopathy.

The present invention discloses a method of treating the infarcted myocardial tissue, including the concentration of SDF-1 protein in the infarcted tissue. The concentration of stem cells in the peripheral blood of the infarcted tissue is also increased. When the concentration of SDF-1 protein in the infarcted tissue is increased, the number of stem cells in the peripheral blood is also increased at the same time.

The invention belongs to the technical field of biological medicine, and particularly relates to a triazolone-thiadiazole compound capable of promoting regeneration of myocardial cells and a drug use of the triazolone-thiadiazole compound. The compound comprises two 3,6-bis-substituted triazolone-thiadiazole derivatives or salts thereof: a chemical structural formula is C14H15N5S, an average molecular weight is 285.37 g / Mol, and the name is 6-cyclohexyl-3-(pyridine-4-yl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole; a chemical structural formula is C13H13N5S, an average molecular weight is 271.37g / mol, and the name is 6-cyclopentyl-3-(pyridine-4-yl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole. An experiment result shows that the small molecular compound is a Wnt / beta-catenin signal channel inhibitor and can effectively promote the proliferation of the myocardial cells and / or restoring the damaged myocardial cells; and an integral-mode animal model experiment shows that the triazolone-thiadiazole compound is hardly toxic, has a further research and application prospect, and can be used for preparing drugs for treating and preventing the diseases such as myocardial infarction, arrhythmia, ischemic cardiomyopathy, cardiac failure and the like.